1. DSpace at Riga Stradiņš University

Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 23 (Search time: 0.002 seconds).
Item hits:
Issue DateTitleAuthor(s)
8-Feb-2015High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patientsKalniete, Dagnija; Nakazawa-Miklaševiča, Miki; Štrumfa, Ilze; Abolinš, Arnis; Irmejs, Arvids; Gardovskis, Janis; Miklaševičs, Edvins; RSU Institute of Oncology; Rīga Stradiņš University
5-Jun-2018High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder populationMaksimenko, J.; Irmejs, A.; Trofimovičs, G.; Berziņa, D.; Skuja, E.; Purkalne, G.; Miklaševičs, E.; Gardovskis, J.; RSU Institute of Oncology
27-Apr-2018Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer : A retrospective cohort analysis and literature reviewSæther, Nikolai Havn; Skuja, Elina; Irmejs, Arvids; Maksimenko, Jelena; Miklasevics, Edvins; Purkalne, Gunta; Gardovskis, Janis; Rīga Stradiņš University
9-Nov-2017Detection of circulating miRNAs : comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patientsEndzelinš, Edgars; Berger, Andreas; Melne, Vita; Bajo-Santos, Cristina; Sobolevska, Kristlne; Abols, Arturs; Rodriguez, Marta; Šantare, Daiga; Rudnickiha, Anastasija; Lietuvietis, Vilnis; Llorente, Alicia; Line, Aija; Rīga Stradiņš University
18-May-2016Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer : A systematic reviewEndzeliņš, Edgars; Melne, Vita; Kalniņa, Zane; Lietuvietis, Vilnis; Riekstiņa, Una; Llorente, Alicia; Line, Aija; Rīga Stradiņš University
1-Feb-2019UEG Young Talent Group : What do we do?Acedo, Pilar; Heinrich, Henriette; van Herwaarden, Yasmijn; Nakov, Radislav; Nitsche, Ulrich; Rodríguez-Lago, Iago; Salaga, Maciej; Skuja, Vita; Rīga Stradiņš University
2016Squamous cell carcinoma "transformation" concurrent with secondary T790M mutation in resistant EGFR-mutated adenocarcinomasJukna, Agita; Montanari, Gloria; Mengoli, Maria Cecilia; Cavazza, Alberto; Covi, Marisa; Barbieri, Fausto; Bertolini, Federica; Rossi, Giulio; Department of Pathology
2012Midline involvement as a risk factor for vulvar cancer recurrenceStankeviča, Jekaterīna; Macuks, Ronalds; Baidekalna, Ieva; Donina, Simona; Department of Obstetrics and Gynaecology
29-Oct-2010Population screening for hereditary and familial cancer syndromes in Valka district of LatviaVanags, Andrejs; Štrumfa, Ilze; Gardovskis, Andris; Borošenko, Viktors; Aboliņš, Arnis; Teibe, Uldis; Trofimovičs, Genadijs; Miklaševičs, Edvins; Gardovskis, Janis; Hereditary Cancer Research Department
25-May-2018Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC) : An open-label, non-randomized, multicenter, phase IV clinical trialMarkóczy, Zsolt; Sárosi, Veronika; Kudaba, Iveta; Gálffy, Gabriella; Turay, Ülkü Yilmaz; Demirkazik, Ahmet; Purkalne, Gunta; Somfay, Attila; Pápai-Székely, Zsolt; Rásó, Erzsébet; Ostoros, Gyula; RSU Institute of Oncology

Discover